{
  "question_stem": {
    "en": "Appropriate treatment is begun, and the patient reports significant symptom improvement. However, she now has abdominal cramping, nausea, sweating, and diarrhea. Which of the following agents can be used to effectively control these new symptoms?",
    "zh": "开始适当的治疗，患者报告症状明显改善。然而，她现在出现腹部绞痛、恶心、出汗和腹泻。以下哪种药物可用于有效控制这些新出现的症状？"
  },
  "question": {
    "en": "Which of the following agents can be used to effectively control these new symptoms?",
    "zh": "以下哪种药物可用于有效控制这些新出现的症状？"
  },
  "options": {
    "A": {
      "en": "Fluoxetine",
      "zh": "氟西汀"
    },
    "B": {
      "en": "Glycopyrrolate",
      "zh": "格隆溴铵"
    },
    "C": {
      "en": "Pilocarpine",
      "zh": "毛果芸香碱"
    },
    "D": {
      "en": "Prazosin",
      "zh": "哌唑嗪"
    },
    "E": {
      "en": "Propranolol",
      "zh": "普萘洛尔"
    }
  },
  "correct_answer": "B",
  "explanation": {
    "en": "The patient is likely experiencing muscarinic overstimulation due to her treatment for myasthenia gravis. First-line treatment for myasthenia gravis (MG) involves the use of cholinesterase inhibitors, such as pyridostigmine, which inhibit the degradation of acetylcholine in the neuromuscular junction, prolonging the action of acetylcholine. Because it increases the concentration of acetylcholine, it increases the stimulation of both nicotinic receptors, which are impacted in MG, and muscarinic receptors, which are normal in MG. Therefore, acetylcholinesterase inhibitors improve skeletal muscle weakness but can cause MUSCARINIC OVERSTIMULATION of the smooth muscles and excessive glandular secretions (eg, diarrhea, diaphoresis, abdominal cramping, emesis).\n\nSelective muscarinic antagonists (eg, glycopyrrolate, hyoscyamine, propantheline) can be used to reduce the adverse effects of cholinesterase inhibitors in sites where acetylcholine action is mediated by muscarinic receptors (ie, gastrointestinal tract). Because of their selectivity, these drugs improve adverse effects without affecting the action of cholinesterase inhibitors on skeletal muscle.\n\n(Choice A) Fluoxetine is a selective serotonin reuptake inhibitor used primarily in the treatment of depression. It acts in a fashion similar to the cholinesterase inhibitors in that it prolongs the activity of a neurotransmitter on its target tissue. However, fluoxetine is otherwise unrelated to cholinesterase inhibitors or their effects.\n\n(Choice C) Pilocarpine is a nonselective muscarinic receptor agonist often used to improve symptoms of dry mouth (ie, gastrointestinal tract). Use of this agent would worsen this patient's side effects.\n\n(Choices D and E) Prazosin is an alpha-1 adrenergic antagonist and propranolol is a beta-adrenergic antagonist; these agents can be used to treat hypertension. Use of either agent does not prevent the adverse effects of a cholinesterase inhibitor.\n\nEducational objective:\nThe treatment of myasthenia gravis involves the use of acetylcholinesterase inhibitors. Adverse effects are related to muscarinic overstimulation, which can be ameliorated by the use of an antimuscarinic agent such as glycopyrrolate.",
    "zh": "患者很可能正在经历毒蕈碱受体过度刺激，这是由于她治疗重症肌无力所致。治疗重症肌无力 (MG) 的一线药物包括胆碱酯酶抑制剂，例如吡啶斯的明，它们抑制神经肌肉接头处乙酰胆碱的降解，延长乙酰胆碱的作用。因为它增加了乙酰胆碱的浓度，所以它增加了对烟碱受体（在 MG 中受到影响）和毒蕈碱受体（在 MG 中正常）的刺激。因此，乙酰胆碱酯酶抑制剂可改善骨骼肌无力，但可引起平滑肌的毒蕈碱过度刺激和过度腺体分泌（如腹泻、发汗、腹部绞痛、呕吐）。\n\n选择性毒蕈碱受体拮抗剂（例如，格隆溴铵、天仙子胺、丙胺太林）可用于减少胆碱酯酶抑制剂在乙酰胆碱作用由毒蕈碱受体介导的部位（即胃肠道）的不良反应。由于它们的选择性，这些药物可改善不良反应，而不会影响胆碱酯酶抑制剂对骨骼肌的作用。\n\n（选项 A）氟西汀是一种选择性 5-羟色胺再摄取抑制剂，主要用于治疗抑郁症。它的作用方式与胆碱酯酶抑制剂相似，即延长神经递质在其靶组织上的活性。然而，氟西汀与胆碱酯酶抑制剂或其作用无关。\n\n（选项 C）毛果芸香碱是一种非选择性毒蕈碱受体激动剂，常用于改善口干症状（即胃肠道）。使用该药会加重患者的副作用。\n\n（选项 D 和 E）哌唑嗪是一种 α-1 肾上腺素能受体拮抗剂，普萘洛尔是一种 β-肾上腺素能受体拮抗剂；这些药物可用于治疗高血压。使用任何一种药物都不能预防胆碱酯酶抑制剂的不良反应。\n\n教育目标：\n重症肌无力的治疗涉及使用乙酰胆碱酯酶抑制剂。不良反应与毒蕈碱过度刺激有关，这可以通过使用抗毒蕈碱药物（如格隆溴铵）来缓解。"
  },
  "summary": {
    "en": "This question tests the understanding of the adverse effects of cholinesterase inhibitors used in the treatment of myasthenia gravis and the appropriate management of these side effects. It specifically assesses knowledge of muscarinic overstimulation and the use of selective muscarinic antagonists.\n\nTo solve this question, identify the symptoms as indicative of muscarinic overstimulation secondary to acetylcholinesterase inhibitor therapy. Then, recall or deduce that selective muscarinic antagonists are used to counteract these specific cholinergic side effects without interfering with the therapeutic effect on skeletal muscle.",
    "zh": "本题考察对用于治疗重症肌无力的胆碱酯酶抑制剂的不良反应及其对这些副作用的适当处理的理解。它特别评估对毒蕈碱过度刺激和选择性毒蕈碱受体拮抗剂使用的知识。\n\n要解决这个问题，首先确定这些症状表明继发于乙酰胆碱酯酶抑制剂治疗的毒蕈碱过度刺激。然后，回想起或推断出使用选择性毒蕈碱受体拮抗剂来对抗这些特定的胆碱能副作用，而不会干扰对骨骼肌的治疗效果。"
  },
  "tags": "Myasthenia gravis; Cholinesterase inhibitors; Muscarinic overstimulation; Antimuscarinic agents; Glycopyrrolate; Diarrhea; Nausea; Sweating; Abdominal cramping; Pharmacology",
  "category": "Neuro",
  "question_id": "2062",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Neuro 24\\2062",
  "extracted_at": "2025-11-05T19:39:06.601892",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 2,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T18:39:01.316695",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}